Mirum Pharmaceuticals Inc MIRM
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-07-18 |
| Shares Out. | 60,980,000 |
| Website | mirumpharma.com/ ↗ |
| Phone | 13023368212 |
| Employees | 418 |
| Revenue | $159.9M |
| Gross Profit | $131.1M |
| Net Income | -$790.2M |
| Free Cash Flow | -$172.6M |
| Total Assets | $890.9M |
| Total Liabilities | $648.4M |
| Equity | $242.5M |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Mirum Pharmaceuticals Inc is a publicly traded company under the ticker symbol MIRM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)